"The weight-loss drug semaglutide cuts the risk of heart attack or stroke regardless of how many kilograms people lose, the largest study of its kind has found. However, shrinking waist size a sign of less belly fat was linked to better heart outcomes, according to the research. The findings, published in the Lancet, suggest drugs could have wider benefits for patients beyond weight loss so should not be restricted to the most obese patients."
"Previous analysis of the data found that semaglutide reduced the risk of major adverse cardiac events by 20%. Researchers have now found the benefit was apparent regardless of how much weight people lost while taking the drug. Academics said the findings suggested there were multiple ways the drug could benefit the heart, rather than the protective effect achieved solely by weight loss alone."
Semaglutide, the active ingredient in Wegovy, lowered the risk of major adverse cardiac events by 20% among 17,604 adults aged 45 and older who were overweight or obese. Weekly injections were compared with placebo across 41 countries, and outcomes included cardiovascular death, heart attack, and stroke. Cardiovascular benefit occurred regardless of total kilograms lost and was largely independent of weight loss in the first four months. Waist circumference reduction, a marker of reduced belly fat, was associated with better heart outcomes and accounted for an estimated one-third of the observed cardiovascular benefit. Benefits applied across BMI levels, including around 27.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]